Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Pharmacovigilance and Risk Management Strategies Conference
Session 5: Hot Topics – Handling Emerging Trends in Pharmacovigilance
Session Chair(s)
Barbara Morollo, RN
- Head, Pharmacovigilance
- Corbus Pharmaceuticals, United States
Catherine Baldridge, MSc
- Founder/Owner, Principal Consultant
- Essential Pharmacovigilance, LLC, United States
This session will explore three hot topics and emerging trends in pharmacovigilance which include spanning discussions regarding predictive safety using translational data and non-clinical data for predicting ADRs, the impact of cannabinoids as therapeutics and research into the endocannabinoid system.
Learning Objective : At the conclusion of this session, participants should be able to:- Understand the technology and factors that contribute to the ability to predict an adverse events or adverse event in a specific population
- Identify the unique regulatory challenges surrounding cannabis and studying therapeutic benefits in investigational research
Speaker(s)
Cannabinoids as Therapeutics
Barbara Morollo, RN
- Head, Pharmacovigilance
- Corbus Pharmaceuticals, United States
Speaker
Glenn Carroll, MBA
- Principal, Strategy | Life Sciences
- Deloitte, United States
Yellow Card Biobank
Sarah Vaughan
- Pharmacovigilance Information Unit Systems Manager
- Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
Contact us
Registration Questions?
Preconference Short Courses
Short Course 1: Pharmacovigilance and Risk Management Planning
Short Course 2: Interdisciplinary Safety Evaluation During Product Development
Short Course 3: Reference Safety Information
Short Course 4: Introduction to Statistics in Pharmacovigilance
Short Course 5: Pharmacovigilance for Medication Errors
On Demand Content Preview Webinar
Preparing for PV Inspections – Beyond the Basics
Download eBook
Pharmacovigilance and Risk Management in 2020: A Global Perspective